Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmacia and Upjohn
• Treatments: Delavirdine; Didanosine; Nelfinavir; Stavudine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are at least 18 years old.

• Are HIV-positive.

• Have a CD4 count of at least 50 cells/mm3.

• Have a viral load of at least 20,000 copies/ml.

Exclusion Criteria

You will not be eligible for this study if you:

• Have taken d4T.

• Have taken protease inhibitors, including NFV.

• Have taken nonnucleoside reverse transcriptase inhibitors.

• Have taken ddI for 1 month or more.